Plant-based vaccines utilize plants like tobacco, potato, etc. to express vaccine antigens which can generate protective immune responses against various diseases. As plants are inexpensive to grow and easy to harvest on a large scale, they provide an economic and scalable platform for vaccine production compared to traditional egg- or cell-based systems.
Method of Vaccine Production Using Plants
The common method used for production of plant-based vaccines involves the genetic engineering of plants to synthesize vaccine immunogens. Specific genes encoding important vaccine antigens are isolated, modified if required, and then introduced into the plant genome using transgenic techniques like agrobacterium-mediated transformation or particle bombardment. The transgenic plants are regenerated from transformed plant cells or tissues and grown in the field or greenhouses. The vaccine antigens undergo folding, post-translational modifications and accumulate to significant levels in parts like leaves, seeds or roots of the plants. These plant tissues containing the antigens are harvested, processed and vaccine immunogens are purified using standard downstream processing methods. The purified immunogens can be directly administered orally or by injection to elicit protective immune responses.
Advantages of Plant-based Vaccines
Some key advantages offered by plant-based vaccine production include:
Cost-effectiveness: Plants provide a low-cost alternative to industrialized methods for vaccine production. Large-scale farming of plants is economical and can greatly reduce vaccine production costs compared to conventional systems.
Scalability: Greenhouses or fields can be rapidly set up to grow plants engineered for vaccine production. Also, plants can accumulate vaccine proteins to high levels, allowing for mass production. This scalability helps meet the global demand for vaccines more readily.
Thermostability: A majority of orally delivered plant-based vaccines are thermostable and do not require refrigeration during transport or storage, eliminating cold chain requirements. This improves their accessibility especially in remote areas lacking modern health infrastructure.
Safety: Plants typically lack infectious agents affecting humans or livestock. Hence, plant-made vaccines carry a lower risk of contamination than egg- or cell-based systems. Also, plant cells do not support the replication of mammalian viruses, eliminating the need to inactivate them.
Oral delivery: Some plant-based vaccine antigens can be delivered orally as they are taken up from the gut, offering the possibility of non-invasive vaccination. This is more acceptable compared to injections.
Potential Applications
Plant-based vaccines are being explored for a range of infectious diseases particularly in developing countries. Some diseases they target include:
Influenza: Tobacco and other plant platforms have been developed to produce influenza vaccines more affordably worldwide, including both seasonal and pandemic strains.
Hepatitis B: Transgenic plants like tomato, potato, tobacco have produced functional Hepatitis B surface antigen particles providing protection in animal trials. This can help control Hepatitis B prevalence globally.
Cholera: Human trials of an edible recombinant cholera toxin B subunit plant-based vaccine have shown safety and immune responses. Its oral delivery overcomes the need for trained healthcare workers to administer injections.
Rabies: Experiments using potato and tobacco as expression systems for the rabies virus glycoprotein indicate their effectiveness as oral rabies vaccines. This can facilitate mass dog vaccination programs in developing nations.
Regulatory Roadblocks
While plant-based vaccines offer clear public health and manufacturing advantages, some challenges still remain for their widespread clinical and commercial use:
Clinical trials data: More extensive phase I-III human clinical trials data needs to be generated to comprehensively demonstrate safety and efficacy profiles as per regulatory standards.
Scale-up and GMP production: Establishing industrial-scale Good Manufacturing Practice compliant production facilities capable of supplying global vaccine demands presents hurdles.
Regulatory approval: Current international regulations primarily designed for traditional vaccine platforms necessitate adaptations to support plant-based vaccines, with guidelines yet to be established in many countries.
Public perception: Possible concerns from some sections of the public regarding genetically modified crops expressing pharmaceuticals also needs to be addressed through open communication.
Future Prospects
With ongoing research efforts addressing these challenges, plant-based vaccines are likely to play an increasing role in tackling infectious diseases globally in the coming decades. Their low-cost and thermostable characteristics will prove especially critical for resource-poor settings. Development of production platforms for other high priority diseases like HIV, malaria is also underway. As regulatory policies evolve to facilitate clinical translation, plant-made vaccines ultimately have the potential to transform global vaccination programs through their scalable and economically sustainable approach.
In summary, plant-based production systems provide a promising alternative for meeting the extensive requirements of mass vaccination in an affordable, sustainable manner. While continued progress is still warranted, ongoing advances clearly demonstrate the feasibility of this technology to strengthen immunization coverage worldwide and tackle both prevalent endemic diseases as well as future pandemics. With coordinated efforts from researchers, industry and regulatory bodies, plant-made vaccines have immense potential to shape the future of global public health.
Get more insights on Plant-Based Vaccines
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
Comments
0 comment